- Reducing mortality rate The leading safety objectives are to determine the effect of administering a dose of 2.6 mg/kg intravenous (IV) infusion of NA-1 to subject with acute stroke who are selected for endovascular revascularization on serious adverse events (SAEs) and 90-day mortality.